KR20100080277A - Method of processing roots of korea ginseng - Google Patents
Method of processing roots of korea ginseng Download PDFInfo
- Publication number
- KR20100080277A KR20100080277A KR1020090016428A KR20090016428A KR20100080277A KR 20100080277 A KR20100080277 A KR 20100080277A KR 1020090016428 A KR1020090016428 A KR 1020090016428A KR 20090016428 A KR20090016428 A KR 20090016428A KR 20100080277 A KR20100080277 A KR 20100080277A
- Authority
- KR
- South Korea
- Prior art keywords
- ginseng
- hemp
- steamed
- weight ratio
- concentrate
- Prior art date
Links
- 241000208340 Araliaceae Species 0.000 title claims abstract description 144
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 title claims abstract description 134
- 235000003140 Panax quinquefolius Nutrition 0.000 title claims abstract description 134
- 235000008434 ginseng Nutrition 0.000 title claims abstract description 134
- 238000000034 method Methods 0.000 title claims abstract description 36
- 239000012141 concentrate Substances 0.000 claims abstract description 54
- 238000010025 steaming Methods 0.000 claims abstract description 50
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 30
- 238000001035 drying Methods 0.000 claims abstract description 21
- 229930182494 ginsenoside Natural products 0.000 claims abstract description 21
- 238000002156 mixing Methods 0.000 claims abstract description 17
- 229940089161 ginsenoside Drugs 0.000 claims abstract description 13
- 230000032683 aging Effects 0.000 claims abstract description 12
- 239000002689 soil Substances 0.000 claims abstract description 11
- 244000025254 Cannabis sativa Species 0.000 claims description 73
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 claims description 73
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 claims description 73
- 235000009120 camo Nutrition 0.000 claims description 73
- 235000005607 chanvre indien Nutrition 0.000 claims description 73
- 239000011487 hemp Substances 0.000 claims description 73
- 239000000203 mixture Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 4
- 239000011259 mixed solution Substances 0.000 claims 1
- 235000020710 ginseng extract Nutrition 0.000 abstract 3
- 229910052571 earthenware Inorganic materials 0.000 abstract 1
- 235000008504 concentrate Nutrition 0.000 description 40
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 229940107131 ginseng root Drugs 0.000 description 10
- 230000001093 anti-cancer Effects 0.000 description 9
- 238000007796 conventional method Methods 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 235000013305 food Nutrition 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- 235000002789 Panax ginseng Nutrition 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 150000007949 saponins Chemical class 0.000 description 6
- RWXIFXNRCLMQCD-JBVRGBGGSA-N (20S)-ginsenoside Rg3 Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RWXIFXNRCLMQCD-JBVRGBGGSA-N 0.000 description 5
- 230000003266 anti-allergic effect Effects 0.000 description 5
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 5
- 239000004927 clay Substances 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000005070 ripening Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 3
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- -1 saponin glycosides Chemical class 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- CKUVNOCSBYYHIS-UHFFFAOYSA-N (20R)-ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CCC3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1O CKUVNOCSBYYHIS-UHFFFAOYSA-N 0.000 description 2
- CKUVNOCSBYYHIS-IRFFNABBSA-N (20S)-ginsenoside Rh2 Chemical compound O([C@H]1CC[C@]2(C)[C@H]3C[C@@H](O)[C@H]4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@H]4[C@@](C)(O)CCC=C(C)C)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O CKUVNOCSBYYHIS-IRFFNABBSA-N 0.000 description 2
- CKUVNOCSBYYHIS-LGYUXIIVSA-N 20(R)-Ginsenoside Rh2 Natural products O([C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@H]1C(C)(C)[C@H]2[C@@](C)([C@H]3[C@](C)([C@@]4(C)[C@H]([C@H](O)C3)[C@@H]([C@](O)(CC/C=C(\C)/C)C)CC4)CC2)CC1 CKUVNOCSBYYHIS-LGYUXIIVSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 239000000043 antiallergic agent Substances 0.000 description 2
- 239000002257 antimetastatic agent Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- FVIZARNDLVOMSU-UHFFFAOYSA-N ginsenoside K Natural products C1CC(C2(CCC3C(C)(C)C(O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O FVIZARNDLVOMSU-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229940033134 talc Drugs 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- AGBCLJAHARWNLA-DQUQINEDSA-N Ginsenoside RG2 Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@@](C)(O)CCC=C(C)C)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O AGBCLJAHARWNLA-DQUQINEDSA-N 0.000 description 1
- XIRZPICFRDZXPF-UHFFFAOYSA-N Ginsenoside Rg3 Natural products CC(C)=CCCC(C)(O)C1CCC(C2(CC(O)C3C4(C)C)C)(C)C1C(O)CC2C3(C)CCC4OC1OC(CO)C(O)C(O)C1OC1OC(CO)C(O)C(O)C1O XIRZPICFRDZXPF-UHFFFAOYSA-N 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- SHZGCJCMOBCMKK-JFNONXLTSA-N L-rhamnopyranose Chemical compound C[C@@H]1OC(O)[C@H](O)[C@H](O)[C@H]1O SHZGCJCMOBCMKK-JFNONXLTSA-N 0.000 description 1
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000010304 firing Methods 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- FVIZARNDLVOMSU-IRFFNABBSA-N ginsenoside C-K Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O FVIZARNDLVOMSU-IRFFNABBSA-N 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000006993 memory improvement Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229910052573 porcelain Inorganic materials 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/03—Products from fruits or vegetables; Preparation or treatment thereof consisting of whole pieces or fragments without mashing the original pieces
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/02—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation containing fruit or vegetable juices
- A23L2/08—Concentrating or drying of juices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L3/00—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs
- A23L3/40—Preservation of foods or foodstuffs, in general, e.g. pasteurising, sterilising, specially adapted for foods or foodstuffs by drying or kilning; Subsequent reconstitution
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 종래 삼(蔘)을 특정 고온 및 고압 조건하에서 가압하여 증숙하는 대신, 삼 및 삼 농축액을 혼합하고 이들을 무압력 증숙기에서 수회 반복 증숙하여 진세노사이드의 함유량을 증가시키는 삼의 신규 흑삼화 제조방법에 관한 것이다. The present invention is a novel black ginseng of ginseng that increases the content of ginsenosides by mixing ginseng and hemp concentrates and steaming them several times in a pressureless steamer instead of steaming steamed ginseng under specific high temperature and high pressure conditions. It relates to a shoe manufacturing method.
삼(蔘) 성분 중 사포닌 배당체는 항암, 항알레르기, 항염증 외에, 중추억제 및 정신안정, 진통, 기억력 개선, 단백질 및 신장 사구체 비대억제, 항당뇨, 항산화 활성물질 생성 촉진, 면역조절, 혈소판 응집억제, 만성신부전증의 치료 효과 등에 약리 효능이 있다. Among the three components, saponin glycosides are anti-cancer, anti-allergic, anti-inflammatory, central repression and mental stability, analgesic, memory improvement, protein and renal glomerular hypertrophy, anti-diabetic, antioxidant active substance production, immune regulation, platelet aggregation It has pharmacological effects such as suppression and treatment effect of chronic kidney failure.
이러한 사포닌은 치환기에 결합된 당 (glucose, arabinose, rhamnose)의 종류와 이들의 수에 따라 다양한 진세노사이드 (ginsenoside)로 분류된다. 상기 진세노사이드 중에서, 특히 치환기에 글루코오스 (glucose) 한 분자가 결합된 진세노사이드 Rh2와 compound K는 항암, 항알레르기, 항염증 효과가 우수한 동시에, 당쇄의 결합이 많지 않아 친수성이 낮아서 장내 흡착 및 흡수율이 우수하다. 그러나 이러한 진세노시드 Rh2, 컴파운드 K 는 인삼에 전혀 함유되어 있지 않거나 극소량 함유되어 있다. 이러한 사항은 항암 활성을 갖는 진세노사이드 Rg2, Rg3의 경우에도 마 찬가지이다.These saponins are classified into various ginsenosides depending on the types of sugars (glucose, arabinose, rhamnose) bound to the substituents and their number. Among the ginsenosides, in particular, ginsenoside Rh2 and compound K, in which a molecule of glucose is bonded to a substituent, have excellent anti-cancer, anti-allergic, and anti-inflammatory effects, and at the same time, due to low hydrophilicity due to low binding of sugar chains, Excellent water absorption. However, these ginsenosides Rh2, compound K are not contained in the ginseng at all or very small amounts. The same is true for ginsenosides Rg2 and Rg3 which have anticancer activity.
한편, 이러한 삼(蔘)을 수회 반복하여 증숙하면 홍삼, 또는 나아가 검붉은 색의 흑삼(黑蔘)으로 가공되어 전술한 진세노사이드의 함량이 증가하게 된다. 이러한 홍삼 또는 흑삼의 제조법은 100℃ 이상의 고온과 대기압 이상의 고압 조건하에서 가압하여 증숙하는 것이 일반적이다. 그러나 이 경우 전술한 공정 조건을 만족시키기 위한 가압기의 사용이 필수적으로 요구되며, 이로 인해 생산성 및 경제성 저하가 초래된다. On the other hand, repeated steaming such ginseng (수) several times is processed into red ginseng, or even dark red ginseng (黑 검) to increase the content of the above ginsenosides. The manufacturing method of such red ginseng or black ginseng is generally steamed by pressurization under high temperature conditions of 100 ° C or higher and high pressure of atmospheric pressure or higher. In this case, however, the use of a pressurizer to satisfy the above-mentioned process conditions is indispensable, which leads to a decrease in productivity and economic efficiency.
본 발명자들은 가압기의 사용이 요구되는 종래 증숙 공정을 적용하는 대신, 삼과 삼의 농축액을 혼합한 후 100℃ 미만의 온도와 대기압 조건하에서 증숙공정과 건조공정을 수회 반복하면, 특정 진세노사이드의 함량이 유의적으로 증가된 흑삼을 얻을 수 있을 뿐만 아니라, 흑삼화 공정의 생산성 및 경제성이 동시에 향상될 수 있음을 확인함으로써 본 발명을 완성하였다. Instead of applying a conventional steaming process that requires the use of a pressurizer, the present inventors have repeated the steaming and drying processes several times under a temperature and atmospheric pressure of less than 100 ° C after mixing hemp and hemp concentrates, and the content of a specific ginsenoside. The present invention was completed by confirming that not only this significantly increased black ginseng can be obtained, but also the productivity and economics of the black ginseng process can be improved at the same time.
본 발명은 이에 기초한 것이다. The present invention is based on this.
본 발명은 삼(蔘)과 삼 농축액을 1: 1~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 0.6~5 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 증숙하고, 상기 증숙된 삼의 수분 함량이 5% 이하로 건조하는 단계를 1~10회 반복하여 유효성분인 진세노사이드 (ginsenoside)의 함량을 증가시키 는 것이 특징인 삼(蔘)의 흑삼화 방법을 제공한다.In the present invention, after mixing the hemp and hemp concentrate in a 1: 1 to 3 weight ratio, the hemp concentrate and water were added in a 1: 0.6 to 5 weight ratio, and the mixed mixture was 95-99 in a pressureless steamer. Steaming in the range of ℃, the water content of the steamed ginseng to repeat the step of drying up to 5% 1 to 10 times, characterized by increasing the content of ginsenoside (ginsenoside) as an active ingredient Provides a method of black ginseng.
이때 상기 삼(蔘)은 건조된 상태의 삼일 수 있다. In this case, hemp (蔘) may be a hemp in a dried state.
또한, 본 발명은 유약사용이 배제되고 제주토로 제작된 옹기에서 산삼 배양근을 1~6개월 동안 상온에서 1차 숙성하고, 1~2년 동안 상온에서 2차 숙성한 후, 숙성된 용액부피 100% 대비 10~40% 가 되도록 무압력 농축기에서 농축하여 형성되는 것이 특징인 삼 농축액의 제조방법을 제공한다.In addition, the present invention excludes the use of glaze and fermented wild ginseng culture roots at room temperature for 1 to 6 months in the Onggi made of Jeju, and after the second ripening at room temperature for 1 to 2 years, the solution volume 100% It provides a method for producing hemp concentrate, characterized in that it is formed by concentration in a pressureless concentrator to 10 to 40% compared.
아울러, 본 발명은 유약 사용이 배제되고, 제주토로 제작된 삼(蔘) 숙성용 옹기를 제공한다.In addition, the present invention is to exclude the use of glaze, it provides a aging pottery made of jeju soil.
본 발명에서는 흑삼화 공정의 생산성 및 경제성을 향상시키면서도, 진세노사이드의 함량이 유의적으로 증가되는 삼의 신규 흑삼화 방법을 제공할 수 있다.In the present invention, while improving the productivity and economics of the black ginseng process, it is possible to provide a novel black ginseng method of ginseng with a significant increase in the content of ginsenosides.
이하, 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명에 따른 삼의 흑삼화 제조방법은, 건조된 삼(蔘)과 삼 농축액을 특정 중량비, 예컨대 1 : 1~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 0.6~5 중량비로 투입하여 혼합된 혼합물을 100℃ 미만의 온도와 무압력 증숙기에서 1회 이상 복수 회, 예컨대 1~10회, 바람직하게는 1~6회 동안 반복하여 증숙 및 건조하는 단계를 포함한다. In the method for producing black ginseng of ginseng according to the present invention, after mixing dried ginseng and ginseng concentrate in a specific weight ratio, such as 1: 1 to 3 weight ratio, the ginseng concentrate and water are 1: 0.6-5 weight ratio. The mixed mixture is introduced into steam and dried at a temperature of less than 100 ℃ at a pressureless steamer one or more times, such as 1 to 10 times, preferably 1 to 6 times.
이때 증숙 및 건조횟수는 1~6회가 바람직하나, 상기 제조 조건이나 제조단계 횟수 등이 일부 벗어나더라도 본 발명의 범주에 속한다. 또한 상기 무압력 증숙기 는 특별한 압력조건을 가압(加壓)하지 않고, 대기압 조건하에서의 증숙하는 기기를 지칭하는 것이다. In this case, the number of steaming and drying is preferably 1 to 6 times, but falls within the scope of the present invention even if some of the manufacturing conditions and the number of manufacturing steps deviate. Also, the pressureless steamer refers to a device that steams under atmospheric pressure without pressurizing a special pressure condition.
상기 흑삼화 방법의 바람직한 일 실시형태를 들면 하기와 같다. 그러나 전술한 바와 같이 삼과 삼 농축액을 혼용하여 증숙공정과 건조공정을 1회 이상 실시한다면, 하기 방법에 의해 특별히 제한되지 않는다. A preferred embodiment of the black ginseng method is as follows. However, as described above, if a mixture of hemp and hemp concentrates is carried out one or more times, the steaming step and the drying step are not particularly limited by the following method.
(a) 1차 증숙단계(a) first steaming stage
건조된 삼(蔘)과 삼 농축액을 1: 1~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 4~5 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 1차 증숙한 후, 수분 함량이 5% 이하가 되도록 건조한다. The dried ginseng and hemp concentrate were mixed in a 1: 1 to 3 weight ratio, and then the hemp concentrate and water were added in a 1: 4 to 5 weight ratio. The mixed mixture was then heated at 95 to 99 ° C. in a pressureless steamer. After primary steaming in the range, the moisture content is dried to 5% or less.
본 발명에서 삼(蔘)은 그 종류, 원산지 및 형태가 특별히 한정되지 않는다. 일례로, 소정의 전처리를 거치거나 또는 거치지 않은 상태의 삼으로서, 현재 통상적으로 시판되고 있는 백삼, 수삼, 홍삼, 산삼 등의 어떠한 것도 본 발명의 실시에 사용될 수 있다. 또한, 상기 삼(蔘)들을 특정조건에서 조직 배양하여 형성된 배양근(cultured roots of ginseng)을 사용할 수도 있다.In the present invention, hemp is not particularly limited in kind, origin and form. For example, any of commercially available white ginseng, fresh ginseng, red ginseng, wild ginseng and the like may be used in the practice of the present invention as hemp without or without a predetermined pretreatment. In addition, the culture roots (cultured roots of ginseng) formed by the tissue culture under the specific conditions may be used.
백삼은 주로 4~6년근 수삼을 원료로 하여 표피를 제거하거나 또는 제거하지 않고 건조, 가공한 것이다. 가공방법에 따라 직삼, 곡삼, 반곡삼, 생건삼, 미삼 등으로 구분될 수 있다. 상기 수삼은 밭에서 캐낸 후 가공하지 아니한 상태를 지칭하며, 홍삼은 주로 4~6년근 수삼을 선별하여 표피를 제거하지 않은 상태에서 증기로 쪄서 건조시킨 담황갈색 또는 담적갈색 인삼을 지칭한다. 또한 산삼은 일반적으로 천종, 지종, 장뇌의 3종류로 분류되는데, 천종과 지종은 산에서 자연적으로 자생한 야생삼이며, 장뇌산삼은 사람이 산삼 종자를 채취하여 산속에 뿌린 후 야생으로 자라게 한 것을 말한다. 바람직하게는 산삼 배양근이다. 이때 산삼의 배양조건은 당 업계에 알려진 통상적인 방법에 의해 적용 가능하며, 특별히 제한되지 않는다. White ginseng is dried and processed with or without the cuticle, mainly from 4-6 years old ginseng. Depending on the processing method, it can be divided into straight ginseng, grain ginseng, semi-grain ginseng, raw dried ginseng, misam. The ginseng refers to a state not processed after harvesting from the field, and red ginseng mainly refers to pale yellow brown or light red ginseng dried by steaming without removing the epidermis by selecting 4-6 year old ginseng. In addition, wild ginseng is generally classified into three types: cheonjong, jijong, and camphor, and cheonjong and jijong are wild ginseng naturally grown in the mountains. . Preferably, wild ginseng culture root. The culture conditions of wild ginseng can be applied by conventional methods known in the art, it is not particularly limited.
본 발명의 흑삼화 방법에 사용되는 삼의 원산지로는 특별히 한정되지 않으며, 일례로 국내산, 미국산, 일본, 히말라야, 베트남, 중국산을 사용할 수 있다. The origin of hemp used in the method of black ginseng of the present invention is not particularly limited, and for example, domestic, US, Japanese, Himalayan, Vietnamese, and Chinese may be used.
상기 삼의 형태 또한 특별히 한정되지 아니한다. 필요에 따라 통상의 방법으로 멸균시키거나 또는 산처리, 고온처리, 가압처리된 삼을 사용할 수도 있다. The form of said hemp is also not specifically limited. If necessary, sterilized by a conventional method, or acid treated, high temperature treated, pressurized hemp may be used.
삼 농축액과 혼합되기 이전에, 본 발명의 삼은 세척하고 통상의 방법에 따라 건조하는 전처리 단계를 거치는 것이 바람직하다. 일례로, 수확된 삼을 물로 3~5회 깨끗하게 세척한 후 건조 채반에 펼쳐 놓은 후, 배풍 열회수 농산물 자동건조기에 건조 채반을 놓고 80~85℃에서 9~12시간 동안 건조하여 수분이 5% 이하로 되도록 한다. Prior to mixing with the hemp concentrate, the hemp of the present invention is preferably subjected to a pretreatment step of washing and drying according to conventional methods. For example, after washing the harvested hemp 3 to 5 times with water and spread it in a dry tray, place the dry tray in the automatic wind-heat recovery agricultural dryer, and dry it for 9 to 12 hours at 80-85 ℃ to get moisture less than 5%. To be
한편 본 발명의 삼과 혼합되는 삼(蔘) 농축액은, 당 업계에 알려진 통상적인 방법에 따라 농축된 삼 농축액을 제한없이 사용할 수 있다. Meanwhile, the hemp concentrate mixed with hemp of the present invention can be used without limitation the hemp concentrate concentrated according to a conventional method known in the art.
바람직하게는, 유약사용이 배제되고 제주토로 제작된 옹기 내에서 삼(蔘)을 1~6개월 동안 상온에서 1차 숙성하고, 1~2년 동안 상온에서 2차 숙성한 후, 숙성된 용액 부피 100% 대비 40% 이하가 되도록 무압력 농축기에서 농축하여 형성된 삼(蔘) 농축액이다. 이때, 상기 상온 온도범위는 10 ~35℃ 범위일 수 있다. 또한 1차 숙성기간은 30~35일이 바람직하다. Preferably, after the use of glaze and fermented ginseng for 1 to 6 months at room temperature for 1 to 6 months in the Onggi made of Jeju, after the second aged at room temperature for 1 to 2 years, the aged solution volume It is a hemp concentrate formed by concentrating in a pressureless concentrator so as to be 40% or less than 100%. At this time, the room temperature may be in the range of 10 ~ 35 ℃. In addition, the first ripening period is preferably 30 to 35 days.
일반적으로 옹기는 성형하여 구워진 소지(素地) 위에, 표면을 엷게 피복 및 밀착시키기 위한 유리질 소재의 유약을 바른 후 소성하여 제조된다. In general, Onggi is produced by applying a glaze of a glass material to coat and adhere the surface lightly on a baked and molded body.
유약(glaze)은 주성분이 규산 화합물로서, 일반적으로 소지 재료보다 녹는점이 낮은 것을 사용한다. 상기 유약은 소성시 잘 녹아 유동하여 소지에 밀착함으로써 표면에 엷은 유리막을 생성하게 되는데, 이러한 유리막은 표면에 광택을 줄 뿐만 아니라 강도를 더하고 오염을 방지한다. 또한 흡수성을 없애서 물이나 화학약품에 대한 저항성을 증가시키게 된다. 그러나 유약을 사용하여 제조된 일반 옹기는 표면에 형성된 유리막으로 인해 통기성이나 보관성 면에서 물성이 저하되는 문제점이 있다.Glaze is a silicate compound whose main component is generally a melting point lower than that of the base material. The glaze melts well during firing and flows to adhere to the base to produce a thin glass film on the surface. The glass film not only gives a gloss to the surface but also adds strength and prevents contamination. It also eliminates absorbency, increasing resistance to water and chemicals. However, the general pottery manufactured using the glaze has a problem in that the physical properties in terms of breathability or storage due to the glass film formed on the surface.
이에 비해, 제주토(土)는 수축률이 큰 철분, 즉 산화철 (Fe2O3)을 다량 함유하고 점성이 큰 점토이다. 이러한 제주토로 제작된 옹기는 유약을 전혀 사용하지 않고도 붉게 구워지고, 천연의 윤기가 흐르며, 약한 점성을 가진 점토로 성형된 자기에 비하여 더욱 강한 강도와 통기성을 갖는다. 또한 유약을 전혀 바르지 않기 때문에 통기성이 매우 우수하다. 특히, 원적외석 91.9%를 함유하고 있기 때문에 탁월한 보관성을 발휘한다. In contrast, Jeju earth is clay having a high shrinkage rate, i.e., iron oxide (Fe 2 O 3 ), and a large viscosity. The onggi made of Jeju earth is baked red without any glaze, flows naturally, and has stronger strength and breathability than porcelain molded from weakly viscous clay. Also, because it does not apply glaze at all, it is very breathable. In particular, since it contains 91.9% of far infrared rays, it exhibits excellent storage.
상기 제주토(土)는 종래 제주토 옹기를 제작하는데 사용되는 토양이라면 특별히 제한되지 아니하며, 일례로 제주시 한경면 조수리, 고산리, 신평리 일대에서 채취한 비화산회토양일 수 있다. 또한 상기 제주토를 이용하여 옹기를 제작하는 방법은 당 업계에 알려진 통상적인 방법에 따라 제한없이 적용될 수 있다. The jeju soil (土) is not particularly limited as long as it is a conventional soil used to produce jeju soil onggi, for example, may be non-volcanic ash soil collected from the Han Gyeong-myeon joriri, Gosan-ri, Sinpyeongri. In addition, the method of manufacturing the pottery using the jeju soil may be applied without limitation in accordance with conventional methods known in the art.
실제로 본 발명에서와 같이 유약 사용이 배제되고 제주토로 제작된 옹기에 삼을 숙성할 경우, 타지역토 (예, 전남 강진, 일본 오키나와)로 제작된 일반 옹기를 사용하는 경우보다 삼의 색감, 미감, 향기 면에서 탁월한 상승효과를 나타낸다는 것을 확인할 수 있다 (표 3 참조). Indeed, when the use of glaze is excluded and aged in the Onggi made of Jeju soil, as in the present invention, the color and taste of the hemp is better than the case of using ordinary Onggi made of Tajito (eg Jeonnam Gangjin, Okinawa, Japan). It can be seen that it shows an excellent synergistic effect in terms of fragrance (see Table 3).
본 발명의 삼 농축액을 형성하기 위한 원료 삼은, 전술한 바와 같이 그 종류, 원산지 및 형태가 특별히 한정되지 않으며, 바람직하게는 흑삼화되는 삼(蔘)과 동일한 종류의 삼일 수 있다. The raw material for forming the hemp concentrate of the present invention is not particularly limited in kind, origin, and form as described above, and may preferably be the same kind of hemp that is black ginseng.
상기 삼은 특정 크기로 분쇄한 분말 형태로 사용될 수 있다. 이러한 분말 삼을 제주토 제작 옹기 내에서 상온으로 1차 숙성단계 및 2차 숙성단계를 거치게 되면 진한 갈색용액으로 숙성되면서 삼 발효가 최적화된다. 이후 숙성액을 무압력 농축기에서 100~105℃ 온도 범위로 숙성액 100% 대비 10~40%가 되도록 농축하면 진한 갈색의 삼 농축액이 제조된다The hemp may be used in the form of powder ground to a specific size. When the powdered ginseng is subjected to the first and second aging steps at room temperature in Jeju-produced pottery, the fermentation of ginseng is optimized while aging with a dark brown solution. After the aging solution is concentrated in a pressureless concentrator at a temperature range of 100 ~ 105 ℃ to 10 ~ 40% compared to 100% of the aging solution to prepare a dark brown tri-concentrate
상기와 같이 준비된 삼과 삼 농축액을 혼합하여 무압력 증숙기에 투입하는데, 이들의 균일한 혼합을 도모하기 위해서 물을 첨가한다. 이때 삼과 삼 농축액의 성분비 (중량비)는 1 : 1~3 일 수 있으며, 삼 농축액 및 물의 성분비(중량비)는 1 : 4~5 범위일 수 있으나, 이에 특별히 제한되지 않는다. The hemp and hemp concentrate prepared as described above are mixed and introduced into a pressureless steamer, and water is added to achieve uniform mixing thereof. At this time, the component ratio (weight ratio) of hemp and hemp concentrate may be 1: 1 to 3, and the component ratio (weight ratio) of hemp concentrate and water may be in the range of 1: 4 to 5, but is not particularly limited thereto.
상기 증숙 및 건조단계의 조건은 특별히 제한되지 아니하며, 일례로 95~99℃의 온도에서 6~10 시간 정도 1차 증숙한 후, 1시간 정도 경과하여 온도가 75~78℃ 범위로 감온되면 상기 삼을 110~120℃ 온도범위에서 10 시간 이상 건조한다. 삼의 부패 및 변질을 방지하기 위해서, 건조시 수분 함량을 5% 이하가 되도록 조절한다.The conditions of the steaming and drying step is not particularly limited, and for example, after primary steaming for about 6 to 10 hours at a temperature of 95 to 99 ° C., when the temperature is reduced to a range of 75 to 78 ° C. after about 1 hour, the three It is dried for at least 10 hours at 110 ~ 120 ℃ temperature range. In order to prevent rot and deterioration of hemp, the moisture content during drying is adjusted to 5% or less.
(b) 2차 증숙단계 (b) secondary steaming stage
상기 단계 (a)에서 1차 증숙된 삼(蔘)과 삼 농축액을 1 : 1~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 4~5 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 2차 증숙한 후, 수분 함량을 5% 이하로 건조함으로써 연한 흑색의 2차 증숙된 삼이 얻어진다. After mixing the first steamed ginseng and hemp concentrate in the step (a) in a weight ratio of 1: 1 to 3, and adding the three concentrates and water in a weight ratio of 1: 4 to 5, the mixed mixture After secondary steaming in the range of 95-99 ° C. in a pressure steamer, a light black secondary steamed hemp is obtained by drying the moisture content below 5%.
2차 증숙 및 건조 단계에서의 조건은 상기 1차 증숙단계와 동일한 것이 바람직하나, 이에 특별히 제한되지 않는다. Conditions in the secondary steaming and drying step is preferably the same as the primary steaming step, but is not particularly limited thereto.
(c) 3차 증숙단계(c) 3rd steaming stage
상기 단계 (b)에서 2차 증숙된 삼과 삼 농축액을 1 : 2~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 1.3~1.8 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 3차 증숙한 후, 수분 함량을 5% 이하로 건조한다. After mixing the second steamed ginseng and hemp concentrate in the step (b) in a weight ratio of 1: 2 to 3, and then adding the three concentrates and water in a weight ratio of 1: 1.3 to 1.8, the mixed mixture in a pressureless steamer After third steaming in the 95-99 ° C. range, the moisture content is dried to 5% or less.
상기 3차 증숙 단계에서의 조건은 특별히 제한되지 아니하며, 일례로 무압력 증숙기 온도 95~99℃에서 10~12시간 정도 증숙하는 것이 바람직하다. Conditions in the third steaming step is not particularly limited, it is preferable to steam for 10 to 12 hours at 95-99 ℃ pressureless steam as an example.
d) 4차 증숙단계d) 4th steaming stage
상기 단계 (c)에서 3차 증숙된 삼과 삼 농축액을 1 : 2~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 1.3~1.8 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 4차 증숙한 후, 수분 함량을 5% 이하로 건조한다After mixing the third steamed ginseng and hemp concentrate in the step (c) in a weight ratio of 1: 2 to 3, and then adding the three concentrates and water in a weight ratio of 1: 1.3 to 1.8, the mixed mixture was heated in a pressureless steamer. After fourth steaming in the range of 95 ~ 99 ℃, dry the moisture content below 5%.
4차 증숙 및 건조 단계에서의 조건은 상기 3차 증숙단계와 동일한 것이 바람직하나, 이에 특별히 제한되지 않는다. Conditions in the fourth steaming and drying step is preferably the same as the third steaming step, but is not particularly limited thereto.
(e) 5차 증숙단계(e) 5th steaming stage
상기 단계 (d)에서 4차 증숙된 삼과 삼 농축액을 1 : 2~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 0.6 ~1.2 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 5차 증숙한 후, 수분 함량을 5% 이하로 건조한다. In the step (d), the four steamed hemp and hemp concentrate were mixed at a weight ratio of 1: 2 to 3, and then the hemp concentrate and water were added at a weight ratio of 1: 0.6 to 1.2. After the fifth steam in the 95 ~ 99 ℃ range, the moisture content is dried to 5% or less.
상기 5차 증숙 단계에서의 조건은 특별히 제한되지 아니하며, 일례로 무압력 증숙기 온도 95~99℃에서 20~24시간 정도 증숙하는 것이 바람직하다. The condition in the fifth steaming step is not particularly limited, for example, it is preferable to steam for about 20 to 24 hours at a pressureless steamer temperature of 95 ~ 99 ℃.
(f) 6차 증숙단계(f) 6th steaming stage
상기 단계 (e)에서 5차 증숙된 삼과 삼 농축액을 1 : 2~3 중량비로 혼합한 후, 여기에 삼 농축액과 물을 1 : 0.6~1.2 중량비로 투입하여 혼합된 혼합물을 무압력 증숙기에서 95~99℃ 범위에서 6차 증숙한 후, 수분 함량을 5% 이하로 건조한다. After the fifth steamed ginseng and hemp concentrate in step (e) were mixed at a weight ratio of 1: 2 to 3, the mixture and the mixture were added to a weight ratio of 1: 0.6 to 1.2 at a weight ratio, and the mixture was mixed in a pressureless steamer. After sixth steaming in the range of 95-99 ° C., the moisture content is dried to 5% or less.
6차 증숙 단계에서의 조건은 상기 5차 증숙 단계와 동일한 것이 바람직하나, 이에 특별히 제한되지 않는다. Conditions in the sixth steaming step is preferably the same as the fifth steaming step, but is not particularly limited thereto.
상기 6차 증숙단계 이후에, 본 발명은 전술한 증숙단계 및 건조단계를 추가적으로 1~4회 정도 더 반복 실시할 수 있다. After the sixth steaming step, the present invention may additionally repeat the above-described steaming step and drying step 1 to 4 more times.
상기와 같은 방법에 의해 흑삼화된 삼(蔘)은 증숙 횟수에 따라 연한 흑색 내지 진한 흑색을 나타내게 된다. Samsam blackened by the method as described above will be light black to dark black depending on the number of steaming.
또한 삼의 주 성분인 사포닌을 최상으로 끌어올려 다른 종래 삼보다 많은 종류의 사포닌을 포함할 수 있으며, 삼의 표피를 제거하지 않아서 삼의 몸체와 표피 사이에 발생되는 사포닌의 손실을 막을 수 있다. 이때 본 발명에서 용어 "사포닌"은 특별하게 다른 언급이 없는 한, 진세노사이드 (ginsenoside), 즉 인삼 사포닌과 동일한 의미로 사용될 수 있다. In addition, the main component of the ginseng saponin by pulling up the best can contain more than the other types of saponins, and do not remove the epidermis of the ginseng can prevent the loss of saponin generated between the body and the epidermis of the ginseng. In this case, the term "saponin" in the present invention may be used in the same sense as ginsenoside, that is, ginseng saponin, unless otherwise specified.
아울러, 제조 공정에서 삼 조직중의 전분 입자가 졸(sol) 상태에서 겔(gel) 상태로 전환되어 체내 소화 흡수가 개선되고, 유효 성분인 진세노사이드 성분 함량이 유의적으로 증가하게 되므로, 뇌기능 활성, 암세포 전이방지 및 암치료제 면에서 우수한 효능을 발휘할 수 있다. In addition, in the manufacturing process, the starch particles in the three tissues are converted from the sol state to the gel state, thereby improving digestion and absorption in the body and significantly increasing the content of ginsenoside component, an active ingredient, Excellent efficacy in terms of functional activity, cancer cell metastasis prevention and cancer treatment.
특히 본 발명의 흑삼화된 삼은, 가공되지 않은 삼에 비해 매우 높은 진세노사이드 함량률을 보여준다. 일례로, 진세노사이드 Rg3는 가공되지 않은 삼에 비해 대략 97배 정도 증가하였으며, 진세노사이드 Rh2는 3.5 ~10.5배 정도 높은 함유량을 나타낸다 (표 1~2 참조). 따라서 진세노사이드 Rg3와 Rh2가 효능을 발휘하는 혈소판 응집 억제작용, 암세포 증식 억제, 암의 전이 억제작용, 암세포 침윤 억제, 항암제의 항암 활성 증대작용, 항알러지 효과, 항염증 및 암치료 분야에서 유용하게 사용될 것으로 예상된다. In particular, the black ginseng ginseng of the present invention shows a very high ginsenoside content rate compared to the raw ginseng. In one example, ginsenoside Rg3 increased by approximately 97 times compared to untreated ginseng, and ginsenoside Rh2 showed a content of 3.5 to 10.5 times higher (see Tables 1 to 2). Therefore, ginsenosides Rg3 and Rh2 are useful in the fields of platelet aggregation inhibition, cancer cell proliferation inhibition, cancer metastasis inhibition, cancer cell infiltration inhibition, anti-cancer activity enhancement, anti-allergic effect, anti-inflammatory and cancer treatment It is expected to be used.
본 발명에 따라 흑삼화된 삼은 통상의 방법에 따라 분쇄, 동결, 또는 진공건조하여 분말화되거나 또는 주정에 침지시켜 형성된 용액 형태로 복용될 수 있다. 또는 상기 분말이나 용액을 약제, 식품, 건강보조류 등에 첨가될 수 있다. Black ginseng hemp according to the present invention may be taken in the form of a solution formed by pulverization, freezing, or vacuum drying, powdered or immersed in alcohol according to a conventional method. Alternatively, the powder or solution may be added to drugs, foods, health supplements and the like.
본 발명에서 각 단계별(예, 1~6차)로 흑삼화되어 수득된 삼은 자체 내 포함되는 진세노사이드의 종류 및 이의 함량이 각기 상이하다는 특징이 있다. 따라서 6차 증숙단계를 모두 거친 흑삼화된 삼 뿐만 아니라, 1차~5차 증숙단계를 각각 거쳐 수득된 단계별 흑삼화된 삼(蔘)을 필요에 따라 각각 독립적으로 사용할 수 있다. In the present invention, the ginseng obtained by black ginseng in each step (eg, first to sixth order) is characterized in that the types of ginsenosides contained in and the content thereof are different. Therefore, as well as black ginseng hemp through all the sixth steaming step, the black ginseng hemp obtained by each of the first to fifth steaming step can be used independently as needed.
상기 흑삼화된 삼의 복용량은 당 업계의 통상적인 범위 내에서 적절히 조절 가능하다. 이의 바람직한 일례를 들면, 제조된 흑삼화된 삼을 10㎛로 분쇄한 분말을 하루에 0.3~1.0g씩 복용할 수 있으며, 또는 흑삼화된 삼을 주정 (20~25%) 1L에 5~10g을 침지하여 잘 흔들어주면 진한 갈색의 용액이 된다. 이것을 물에 1/2씩 혼합하여 하루에 150~200cc씩 복용할 수 있다. 복용한 이후 다시 주정을 넣으면 5회 정도 사용이 가능하다.The dosage of the black ginseng hemp can be appropriately adjusted within the conventional range in the art. As a preferable example of this, 0.3 to 1.0 g of the powder ground crushed black ginseng ginseng can be taken in a day of 10 μm, or 5 to 10 g of ginseng ginseng ginseng (20 to 25%) in 1 L Dip it and shake well to get a dark brown solution. You can mix this in 1/2 of water and take 150-200cc a day. After taking the alcohol, you can use it five times.
본 발명에 따라 흑삼화된 삼은 항암, 항염증, 항알레르기 등을 위한 약제로 사용될 수 있다. Black ginseng according to the present invention can be used as a medicament for anticancer, anti-inflammatory, anti-allergic and the like.
상기 약제는, 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 파우더, 젤, 연고, 크림 등의 외용제 또는 멸균 주사용액의 형태로 제형화하여 사용될 수 있다. The medicament may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols or the like, external preparations such as powders, gels, ointments, creams or sterile injectable solutions according to a conventional method. Can be used.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 상기 조성물에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트(calcium carbonate), 수크로스(sucrose), 또는 락토오스(lactose), 젤라틴 등을 섞어 조제될 수 있다. 또한 단순한 부형제 이외에, 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상 제재로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제재에는 멸균된 수용 액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in the composition, for example, starch, calcium carbonate, sucrose ( sucrose), or lactose, gelatin and the like may be mixed. In addition to simple excipients, lubricants such as magnesium stearate, talc can also be used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. . Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate and the like can be used.
본 발명의 흑삼화된 삼을 항암, 항염증 또는 항알레르기용 약제로 사용할 경우, 필요에 따라 당 업계에 알려진 통상적인 담체, 부형제 또는 희석제를 추가로 포함할 수 있다. When the black ginseng ginseng of the present invention is used as an anticancer, anti-inflammatory or antiallergic agent, it may further include conventional carriers, excipients or diluents known in the art as needed.
상기 담체, 부형제 또는 희석제로는 락토즈, 덱스트로즈, 수크로스, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피를리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 프로필히드록시벤조에티트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다. 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. The carrier, excipient or diluent may include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline Cellulose, polyvinyl pyridone, water, methylhydroxybenzoate, propylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
본 발명에 따라 흑삼화된 삼을 유효성분으로 함유하는 항암, 항염증 또는 항알레르기용 약제의 바람직한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 투여경로 및 기간에 따라 다르지만, 당업자에 의해 적절하게 선택될 수 있다. 그러나 바람직한 효과를 위해서, 본 발명의 흑삼화된 삼은 1일 0.0001 내지 100 mg/kg으로 투여될 수 있다. 투여횟수, 투여방식 및 투여량은 특별히 제한되지 않으며, 인간을 포함하는 포유동물에 경구, 정맥, 근육 또는 피하 주사 등에 의해 투여 될 수 있다. 필요에 따라 공지된 항암, 항염 또는 항알레르기 효능 물질을 추가로 포함할 수 있다. The preferred dosage of the anti-cancer, anti-inflammatory or anti-allergic agent containing black ginseng ginseng as an active ingredient according to the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the period of time. Can be appropriately selected. However, for the desired effect, the black ginseng hemp of the present invention may be administered at 0.0001 to 100 mg / kg per day. Frequency of administration, mode of administration and dosage are not particularly limited and may be administered to mammals including humans by oral, intravenous, intramuscular or subcutaneous injection. If necessary, it may further include a known anticancer, anti-inflammatory or antiallergic substance.
아울러, 본 발명에 따라 흑삼화된 삼은 건강 기능식품으로 사용될 수 있다. In addition, black ginseng according to the present invention can be used as a health functional food.
상기 흑삼화된 삼을 첨가할 수 있는 식품으로는, 예를 들어, 각종 식품류, 음료, 껌, 차, 비타민 복합제, 건강 기능성 식품류 등이 있다. 건강식품 중의 상기 흑삼화된 삼의 양은 전체 식품 중량의 0.01 내지 15 중량%로 가할 수 있으며, 음료 중의 상기 흑삼화된 삼의 양은 100 ㎖를 기준으로 0.01 내지 20 g, 바람직하게는 0.3 내지 1 g의 비율로 가할 수 있다. 필요에 따라 통상의 여러 가지 향미제, 천연 탄수화물, 기타 통상적인 건강식품 첨가제 등을 추가 성분으로서 함유할 수 있다. Examples of the food to which the black ginseng hemp can be added include various foods, beverages, gums, teas, vitamin complexes, and health functional foods. The amount of black ginseng ginseng in the health food can be added at 0.01 to 15% by weight of the total food weight, the amount of black ginseng ginseng in the beverage is 0.01 to 20 g, preferably 0.3 to 1 g based on 100 ml It can be added at the ratio of. If desired, various conventional flavors, natural carbohydrates, other conventional health food additives, and the like may be included as additional ingredients.
또한 본 발명은 유약사용이 배제되고 제주토로 제작된 옹기에서 삼을 1~6개월 동안 상온에서 1차 숙성하고, 1~2년 동안 상온에서 2차 숙성한 후, 숙성된 용액부피 100% 대비 10~40%가 되도록 무압력 농축기에서 농축하여 형성되는 것이 특징인 삼(蔘) 농축액의 제조방법 및 상기 방법에 의해 제조된 삼 농축액을 제공한다.In addition, the present invention excludes the use of glaze and first aged aged at room temperature for 1 to 6 months in the Onggi made of Jeju, and after the second aged at room temperature for 1 to 2 years, compared to 100% of the aged solution volume 10 It provides a method for producing hemp concentrate, characterized in that it is formed by concentrating in a pressureless concentrator to ˜40%, and hemp concentrate prepared by the method.
삼 농축액의 제조방법은 기언급된 바와 동일하므로 생략하기로 한다. The manufacturing method of hemp concentrate is the same as mentioned above and will be omitted.
상기와 같이 제조된 삼 농축액은 전술한 흑삼화 제조 용도 이외에, 단독적으로 약제, 식품, 건강보조류에 적용될 수도 있다. Hemp concentrate prepared as described above may be applied to pharmaceuticals, food, health supplements alone, in addition to the above-described use of black ginseng.
이때 삼 농축액은 통상의 방법에 따라 농축시키거나 동결 또는 진공건조하여 분말화된 상태로 약제, 식품, 건강 보조류에 적용될 수 있으며, 그 외 농축액 자체를 그대로 복용할 수도 있다. At this time, hemp concentrate can be applied to pharmaceuticals, foods, health supplements in a powdered state by concentrating or freezing or vacuum drying according to a conventional method, the other concentrate may be taken as it is.
아울러, 본 발명은 유약 사용이 배제되고, 제주토로 제작된 삼(蔘) 숙성용 옹기를 제공한다. In addition, the present invention is to exclude the use of glaze, it provides a aging pottery made of jeju soil.
종래 제주옹기는 식품 보관 용도로만 사용되었던 반면, 본 발명에서는 삼(蔘)을 발효 및 숙성시키는 신규 용도로 사용하고자 한다. Conventional Jeju Onggi was used only for food storage, whereas in the present invention, it is intended to be used as a novel use for fermenting and ripening ginseng.
실제로, 제주 옹기를 삼의 숙성용도로 사용하는 경우, 삼의 발효공정을 최적화하여 미감, 색감, 향기 뿐만 아니라, 진세노사이드 함량 면에서 상승효과를 발휘한다는 것을 확인할 수 있다. In fact, when using Jeju Onggi for the aging application of ginseng, it can be seen that by optimizing the fermentation process of ginseng exhibits a synergistic effect in terms of taste, color, fragrance, ginsenoside content.
이하, 본 발명을 실시예에 의해 상세히 설명하기로 한다. 그러나 이들 실시예는 본 발명을 구체적으로 설명하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail by way of examples. However, these examples are intended to illustrate the present invention in detail, and the scope of the present invention is not limited to these examples.
실시예 1 Example 1
1-1. 산삼 배양근 건조1-1. Dry mountain ginseng root
산삼배양근을 수확한 다음 물로 3회 깨끗하게 세척한 후 건조 채반에 3~5cm 두께로 펼쳐 놓고, 배풍열회수 농산물 자동건조기에 건조 채반을 놓고, 수분 함량이 5% 이하가 되도록 80℃에서 9시간 동안 건조하였다. After harvesting wild ginseng roots, wash them cleanly with water three times, spread them 3 ~ 5cm thick in a dry tray, and place the dry tray in an automatic drying machine for breeze heat recovery agricultural products, and dry them at 80 ℃ for 9 hours so that the moisture content is below 5%. It was.
1-2. 산삼 배양근 농축액 제조단계1-2. Production step of wild ginseng culture root concentrate
건조된 산삼 배양근을 10 ㎛로 분쇄하여 40% 주정 100L에 산삼배양근 분말 1,500g (산삼배양근 생체 25Kg 정도)을 유약을 바르지 않은 제주 전통 옹기에 투입하고 30~35일간 실내 (상온)에서 1차 숙성시켰다. 1차 숙성된 용액을 정제하여 제주 전통 옹기에서 1년 이상 실내 (상온)에서 2차 숙성시켰다. 2차 숙성시, 진한 갈색의 용액으로 숙성되면서 향기도 향상되었다. 2차 숙성된 용액 20L를 무압력 농축 기의 온도 100~105℃에서 8L (40%)가 되게 농축하여 진한 갈색의 농축액을 제조하였다. Dry ginseng culture roots were pulverized to 10 μm, and 1,500 g of wild ginseng root powder (approximately 25 kg of ginseng culture roots) was added to the traditional unglazed Jeju Ong, and then aged for 30 to 35 days at room temperature (room temperature). I was. The first aged solution was purified and secondly aged indoors (room temperature) for more than a year in Jeju traditional Onggi. At the time of second ripening, the fragrance was also improved by aging with dark brown solution. 20 L of the second aged solution was concentrated to 8 L (40%) at a pressureless concentrator at 100-105 ° C. to prepare a dark brown concentrate.
1-3. 산삼 배양근 흑삼화 (1차 증숙)1-3. Wild ginseng cultured black ginseng (primary steaming)
상기 실시예 1-1에서 건조된 산삼배양근 3~3.5Kg에 실시예 1-2에서 제조된 산삼 배양근 농축액 6L을 첨가하여 골고루 혼합하여 무압력 증숙기에 투입한 후 물 8L와 산삼 배양근 농축액 2L을 첨가하여 무압력 증숙기 온도를 95~99℃에서 6시간 동안 증숙하였다. 1시간 정도 경과한 후 (75℃) 무압력 증숙기를 열고, 1차 증숙된 산삼배양근을 건조 채반에 1~2cm 두께로 펼쳐 건조기의 온도 110~120℃에서 10시간 동안 수분이 5% 이하로 건조하였다. Add 6L of wild ginseng culture root concentrate prepared in Example 1-2 to 3 ~ 3.5Kg of dried ginseng culture root in Example 1-1, mix evenly, add to the pressureless steamer, add 8L water and 2L of wild ginseng culture root concentrate. Pressureless steamer temperature was steamed for 6 hours at 95 ~ 99 ℃. After 1 hour (75 ℃), open the pressureless steamer, and spread the first steamed wild ginseng root to a thickness of 1 ~ 2cm in the drying tray and dry it to below 5% moisture for 10 hours at 110 ~ 120 ℃ of the dryer. It was.
1-4. 산삼 배양근 흑삼화 (2차 증숙)1-4. Wild Ginseng Cultured Black Ginseng (Second Steaming)
1차 증숙된 산삼 배양근을 사용한 것을 제외하고는, 상기 실시예 1-3과 동일한 방법을 반복 실시하여 2차 증숙된 산삼 배양근을 제조하였다. 제조된 산삼 배양근은 연한 흑색을 나타내었다. Except for using the first steamed wild ginseng culture root, the same method as in Example 1-3 was repeated to prepare a second steamed wild ginseng culture root. The prepared wild ginseng culture root was light black.
1-5. 산삼 배양근 흑삼화 (3차 증숙)1-5. Wild ginseng cultured black ginseng (3rd steaming)
2차 증숙된 산삼 배양근에 실시예 1-2에서 제조된 산삼 배양근 농축액 6L을 첨가하여 골고루 혼합하여 무압력 증숙기에 투입한 후 물 6L와 산삼 배양근 농축액 4L를 넣고 무압력 증숙기 온도를 95~99℃에서 10~12시간 증숙한 것을 제외하고는, 상기 실시예 1-3과 동일한 방법을 반복 실시하여 3차 증숙된 산삼 배양근을 제조하였다.6L of wild ginseng culture root concentrate prepared in Example 1-2 was added to the second steamed wild ginseng root, mixed evenly, put into a pressureless steamer, and 6L of water and 4L of wild ginseng root were added and the pressureless steamer temperature was 95-99. Except that steaming for 10 to 12 hours at ℃, the same method as in Example 1-3 was repeated to prepare a third steamed wild ginseng culture root.
1-6. 산삼 배양근 흑삼화 (4차 증숙)1-6. Wild ginseng cultured black ginseng (4th steam)
3차 증숙된 산삼 배양근을 사용한 것을 제외하고는, 상기 실시예 1-5와 동일한 방법을 반복 실시하여 4차 증숙된 산삼 배양근을 제조하였다. 제조된 산삼 배양근은 흑색을 나타내었다. Except for using the third steamed wild ginseng culture root, the same method as in Example 1-5 was repeated to prepare a fourth steamed wild ginseng culture root. The prepared wild ginseng culture root was black.
1-7. 산삼 배양근 흑삼화 (5차 증숙)1-7. Wild ginseng cultured black ginseng (5th steaming)
4차 증숙된 산삼 배양근에 실시예 1-2에서 제조된 산삼 배양근 농축액 6L을 첨가하여 골고루 혼합하여 무압력 증숙기에 투입한 후 물 5L와 산삼 배양근 농축액 5L를 넣고 무압력 증숙기 온도를 95~99℃에서 20~24시간 증숙한 것을 제외하고는, 상기 실시예 1-3과 동일한 방법을 반복 실시하여 5차 증숙된 산삼 배양근을 제조하였다.After adding 6L of the wild ginseng root extract prepared in Example 1-2 to the fourth steamed wild ginseng root, mixed evenly, put it in a pressureless steamer, and then put 5L of water and 5L of wild ginseng root. Except that steaming for 20 to 24 hours at ℃, the same method as in Example 1-3 was repeated to prepare a fifth steamed wild ginseng culture root.
1-8. 산삼 배양근 흑삼화 (6차 증숙)1-8. Wild ginseng cultured black ginseng (6th steaming)
5차 증숙된 산삼 배양근을 사용한 것을 제외하고는, 상기 실시예 1-7과 동일한 방법을 반복 실시하여 6차 증숙된 산삼 배양근을 제조하였다. 제조된 산삼 배양근은 진한 흑색을 나타내었다.Except for using the fifth steamed wild ginseng culture root, the same method as in Example 1-7 was repeated to prepare a sixth steamed wild ginseng culture root. The prepared wild ginseng culture root was dark black.
실험예 1. 흑삼화된 산삼 배양근의 외관 및 함량 변화Experimental Example 1. Changes in appearance and content of black ginseng cultured wild ginseng root
2차 증숙, 4차 증숙 및 6차 증숙된 산삼 배양근을 각각 사용하여 이들의 색깔과 진세노사이드 (ginsenoside)의 함량 변화를 측정하였으며, 이의 대조군으로 무처리된 산삼 배양근을 사용하였다.The changes of their color and ginsenoside contents were measured using the second, fourth and sixth steamed wild ginseng roots, respectively, and untreated wild ginseng roots were used as control.
이때 산삼 배양근의 진세노사이드 함량시험은 식품의약품안전청고시 건강기능식품에 관한 법률(2006)에 명시된 인삼성분 함량 분석법및 HPLC법으로 시험하였다. 이들의 결과는 하기 표 1 및 2와 같다. At this time, ginsenoside content test of cultured ginseng was tested by ginseng content analysis method and HPLC method specified in the Act on Health Functional Foods when notified by KFDA (2006). These results are shown in Tables 1 and 2 below.
(1) Rg2+Rh1 (뇌기능 활성화 작용)는 2차 증숙시 28mg에서 78mg으로 2.8배가 증가하였으며, 4차 증숙시에는 57mg으로 2.0배 증가하였고, 6차 증숙시에는 38mg으로 1.4배 증가하였다.(1) Rg2 + Rh1 (brain function activating action) increased 2.8-fold from 28mg to 78mg in the second steam , increased 2.0-fold to 57mg in the fourth steam and 1.4-fold to 38mg in the sixth steam.
(2) Rg3 (암세포 전이 방지제)는 2차 증숙시 2mg에서 87mg으로 43배 증가, 4차 증숙시에는 174mg으로 87배 증가하였고, 6차 증숙시에는 194mg으로 97배 증가하였다.(2) Rg3 (cancer metastasis inhibitor) increased by 43 times from 2mg to 87mg in the second steaming, 174mg in the fourth steaming, and 97 times to 194mg in the 6th steaming.
(3) Rh2 (암치료제)는 2차 증숙시 2mg에서 7mg으로 3배 증가, 4차 증숙시에는 21mg으로 10배 증가하였고, 6차 증숙시에는 17 mg으로 8배 증가하였다.(3) Rh2 (cancer treatment) increased threefold from 2mg to 7mg in the second steam, 10-fold to 21mg in the fourth steam, and increased 8-fold to 17mg in the sixth steam.
전술한 결과로 볼 때, 본 발명의 흑삼화 제조방법은 고온과 고압 조건하에서 가압기를 사용하지 않음에도 불구하고, 삼에 유효성분으로 포함된 진세노사이드 (ginsenoside), 특히 Rg2+Rh1 (뇌기능 활성화 작용), Rg3 (암세포 전이 방지제), Rh2 (암치료제) 성분의 함량을 증대시키는 데 매우 효과적이라는 것을 확인할 수 있었다. In view of the above results, the method for producing black ginseng of the present invention, despite not using a pressurizer under high temperature and high pressure conditions, ginsenoside, especially Rg2 + Rh1 (brain function) Activating action), Rg3 (cancer cancer metastasis inhibitor), Rh2 (cancer treatment) component was confirmed to be very effective to increase the content.
실험예 2. 제주토 옹기의 삼 농축액 숙성 고찰Experimental Example 2. Aging of Hemp Concentrate of Jeju Onggi
제주도 옹기와 타지역 (전남 강진, 일본 오키나와) 옹기에서 각기 주정 40%에서 추출한 산삼배양근 농축액의 변화를 하기와 같이 확인하였다. The changes of wild ginseng root concentrations extracted from 40% alcohol in Onggi, Onggi, and other regions (Gangjin, Jeonnam, Japan) were as follows.
실제로, 유약 사용이 배제되고 제주토로 제작된 옹기에서 삼 농축액을 숙성하는 경우, 타지역토를 사용하여 제작된 옹기 및/또는 제주토로 제작된 반면 유약이 사용된 옹기에 비해 색, 감미, 향 면에서 모두 상승효과를 일으켜 우수한 물성을 발휘한다는 것을 알 수 있었다 (표 3 참조).Indeed, when the use of glaze is excluded and the hemp concentrate is aged in the clay made from Jeju, the color, sweetness, and flavor of the clay made from other local clays and / or from Jeju, while the glaze is used, It can be seen that both exhibit synergistic effects and exhibit excellent physical properties (see Table 3).
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/KR2009/007861 WO2010077052A2 (en) | 2008-12-30 | 2009-12-29 | Method for producing black ginseng from ginseng |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020080136649 | 2008-12-30 | ||
| KR20080136649 | 2008-12-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20100080277A true KR20100080277A (en) | 2010-07-08 |
| KR101097664B1 KR101097664B1 (en) | 2011-12-22 |
Family
ID=42641250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020090016428A KR101097664B1 (en) | 2008-12-30 | 2009-02-26 | Method of processing roots of korea ginseng |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101097664B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101359078B1 (en) * | 2011-03-08 | 2014-02-05 | 이홍식 | Method of processing roots of wild ginseng |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102297181B1 (en) | 2021-03-08 | 2021-09-01 | 황치운 | Manufacturing method of black-red ginseng liquid using clay steamer and ginseng solution and manufactruing method of black-red ginseng by the same |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100543862B1 (en) * | 2005-08-01 | 2006-01-23 | (주) 흑삼코리아 | A black ginseng having excel content of active ingredient and the concentrate of black ginseng |
| KR100864471B1 (en) * | 2007-04-25 | 2008-10-20 | 김재경 | A processed ginseng using extract of herb medicine and a producing method thereof |
-
2009
- 2009-02-26 KR KR1020090016428A patent/KR101097664B1/en active IP Right Grant
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101359078B1 (en) * | 2011-03-08 | 2014-02-05 | 이홍식 | Method of processing roots of wild ginseng |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101097664B1 (en) | 2011-12-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100730647B1 (en) | Aged Concentrate of Ginseng Steamed Red, and a Preparation Method Thereof | |
| KR101447486B1 (en) | Method for producing red ginseng water extract with enhanced specific ginsenoside content | |
| CN105941700A (en) | Hippophae rhamnoide-Fu tea and preparation technology thereof | |
| CN101589801B (en) | Process for manufacturing red ginseng honey slice | |
| KR101341755B1 (en) | The effective isolation method of panaxadiol saponin fraction from ginseng using pectinase | |
| KR101963046B1 (en) | Composition of processed ginseng having increased ginsenoside compound K, chlorgenic acid and quercetin, and preparation method thereof | |
| KR101625474B1 (en) | Manufacturing method for mass-production of ginsenoside Rh4 | |
| KR20120066725A (en) | A rice cake with health functionality of wasong flour and extract, and its manufacturing method | |
| KR100921266B1 (en) | Method for producing red-ginseng extract | |
| KR101097664B1 (en) | Method of processing roots of korea ginseng | |
| KR102115622B1 (en) | Pharmaceutical composition comprising the fermentation extract of medicinal or edible natural products as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| CN107417696A (en) | A kind of method that raspberry glycosides and ellagic acid are extracted from raspberry | |
| KR100959496B1 (en) | Blood glucose dropping Mulberry leaf tea cultured with Phellinus Linteus mycelium | |
| KR101409168B1 (en) | Method for manufacturing red ginseng extract with enhanced function and the extact thereof | |
| KR101381277B1 (en) | The wild rice gel containing ginseng | |
| KR20220087888A (en) | Black bellflower syrup and method of preparing therefor | |
| CN109287916A (en) | A kind of preparation method of Sessileflower Acanthopanax Bark extracting solution and its beverage | |
| Gafforov et al. | Ganoderma adspersum (Schulzer) Donk; Ganoderma applanatum (Pers.) Pat.; Ganoderma lucidum (Curtis) P. Karst.; Ganoderma resinaceum Boud.-GANODERMATACEAE | |
| KR101828454B1 (en) | Method of making ginseng containing cinnamon, orostachys japonicus, selaginella tamariscina and low-molecular-weight ginsenosides | |
| CN110537652A (en) | Cordyceps militaris and ginkgo leaf health-care beverage and preparation method thereof | |
| KR101413492B1 (en) | Manufacturing method and makgeolli using red ginseng and lactic acid bacteria | |
| KR102213374B1 (en) | Method for producing red ginseng tea with enhanced 17 gensenosides content | |
| KR102106018B1 (en) | Method For Producing Steaming Ginseng Berry Fermented Extracts Having Preventive and Improving Effects of Liver Damage | |
| KR100525008B1 (en) | Method for preparing compressed ginseng with enhanced content of ginsenosides Rg3 and irradiated ponin | |
| KR101016996B1 (en) | A composition comprising ginsenosides for treating and preventing heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20140926 Year of fee payment: 4 |
|
| FPAY | Annual fee payment |
Payment date: 20150930 Year of fee payment: 5 |
|
| FPAY | Annual fee payment |
Payment date: 20171024 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20181017 Year of fee payment: 8 |